Drug abuse: The addiction of the 21st century?;Abuso de medicamentos: ¿la adicción del siglo XXI?

FMC Formacion Medica Continuada en Atencion Primaria

Volumn 14, Issue 5, 2007, Pages 255-262

  Rafel, Borràs Vives ^a   Susana, Boada Loro ^a   Núria, Casamitjana Cucurella ^a   Xavier, Casas Sánchez ^a   Rafel, Guayta Escolies ^a   Carles, Gironella Ferrer ^a   Gaspar, Linares Bertolín ^a   Lluís, Ortún Andrés ^a   Jesús, Palacio Quilez ^a   Teresa, Videllet Mestres ^a   Cristina, Rodríguez Caba ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE; CODEINE; DEXTROMETHORPHAN; DEXTROPROPOXYPHENE; EPHEDRINE; KETAMINE; METHYLPHENIDATE; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; TRAMADOL;

ARTICLE; DRUG ABUSE; HEALTH CARE ORGANIZATION; HUMAN; SUBSTANCE ABUSE;

EID: 34548096967     PISSN: 11342072     EISSN: 15789675     Source Type: Journal    
DOI: 10.1016/S1134-2072(07)71626-2     Document Type: Article

References (79)

1. National Institute on Drug Abuse [citado 16 May 2006] Disponible en: www. drugabuse.gov
2. Charatan F. Us panel calls for research into effects of Ritalin. BMJ. 1998;317:1545.
3. Goldman LS, Genel M, Bezman RJ, Slanetz PJ. Diagnosis and treatment of attention deficit hyperactivity disorder in children and adolescents. JAMA. 1998;279:1100-7.
4. Jhonston ID, O'Malley PM, Bachman JG. Monitoring the Future: National Survey results on Drug Use. 1975-1999. National Institute for Drug Abuse, 2000.
5. Finch J. Prescription drug abuse. Prim Care. 1993;20:231-9.
6. Isaacson JH, Hopper JA, Alford DP, Parran T. Prescription drug use and abuse. Postgrad Medicine. 2005;118:19-26
7. National Institute on Drug Abuse. NIDA Infofacts: prescription pain and other medications. [citado 3 Oct 2006]. Disponible en www dryabuse. org
8. Reid MC, Engels-Horton LL, Weber MB. Use of opioid medications for chronic noncancer pain syndromes in primary care. J Gen intern Med. 2002;17:173-9.
9. Simoni-Wastila L. The use of abusable prescription drugs: the role of gender. J Womens health Gend Based Med. 2000;9:289-97.
10. Teter CJ, McCabe SE, Cranford JA, Boyd CJ, Guthrie SK. Prevalence and motives for illicit use of prescription stimulants in an undergraduate student sample. J Am Coll Health. 2005;53:253-62.
11. Volkow ND, Swanson JM. Variables that affect the clinical use and abuse of metilphenidate in the treatment of ADHD. Am J Psychiatry. 2003;160:1909-18.
12. Charatan F. Us panel calls for research into effects of Ritalin. BMJ. 1998;317:1545.
13. Goldman LS, Genel M, Bezman RJ, Slanetz PJ. Diagnosis and treatment of attention deficit hyperactive disorder in children and adolescents JAMA. 1998;279:1100-7.
14. Mannuzza S, Klein RG, Bressler A, Mallory P, LaPadula M. Adult psychiatric status of hyperactive boys grown up. Am J Psychiatr. 1998;155:493-8.
15. Johston ID, O'Malley PM, Bachman JG. Monitoring the future: national survey results on drug use. 1975-1999. National Institute for Drug Abuse, 2000.
16. Wilens TE, Faraone SC, Biederman J, Gunawarderene S. Does stimulant therapy of Attention-deficit Hyperactive Disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics. 2003;111:179-85.
17. Wilens TE, Gignac M, Swezey A, Monuteaux MC, Biederman J. Characteristics of adolescents and young adults with ADHD who divert misuse their prescribed medications. J Acad Child Adolesc Psychiatry. 2006;45:408-14.
18. McCabe SE, Teter CJ, Boyd CJ. Medical use, illicit use, and diversión of abusable prescription drugs. J Am Coll Health. 2006;54:269-78.
19. Parran T. Prescription drug abuse: a question of balance. Med Clin North Am. 1997;81:967-78.
20. Mccabe SE, Boyd CJ. Sources of prescription drugs for illicit use. Addict Behav. 2005;30:1342-50.
21. Chait LD. Reinforcing and subjective effects of metilphenidate in humans. Behav Pharmacol. 1994;5:281-8.
22. Leonard BE, Mccartan D, White J, King DJ. Metilphenidate: a review of its neuropharmacological, neurophysiological and adverse clinical effects. Hum Psycopharmacol Clin Exp. 2004;19:151-80.
23. Teter CJ, McCabe SE, Boyd CJ, Guthrie SK. Illicit metilphenidate use in undergraduate student simple: Prevalence and risk factors. Pharmacotherapy. 2003;23:609-17.
24. www.drugfreeaz.org [citado 16 May 2006].
25. National Institute on Drug Abuse. [citado 5 Oct 2006]. Disponible en: www.drugabuse.gov
26. Green SM, Li J. Ketamine in adults: what emergency physicians need to know about patient slection and emergente reactions. Acad Emerg Med. 2000;7:278-81.
27. Kohrs R. Durieux ME. Ketamine: teaching an old drug new tricks. Anesth Analg. 1998;87:1186-93.
28. Krystal JH, Harper LP, Seibyl JP, Freeman GK, delaney R, Bremmer JD, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994;51:199-214.
29. Koesters SC, Rogers PD, Rajasingham CR. MDMA ("ecstasy") and other "club drugs". The new epidemic. Pediatric Clin North Am. 2002;49:415-33.
30. Jansen KL. A review of the nonmedical use of Ketamine: use, users and consequences. J Psychoactive Drugs. 2000;32:419-33.
31. Reich DL, Silvay G. Ketamine: an update on the first twenty-five years of clinical experience. Can Anaesth. 1989;36:186-97.
32. Weiner AL, Vieira L, Mckay CA, Bayer MJ. Ketamine abusers presenting to the emergency department: a case series. J Emerg Med. 2000;18:447-51.
33. Bourke DL, Malit LA, Smith TC. Respiratory interactions of ketamine and morphine. Anesthesiology. 1987;66:153-6.
34. Shomer RR. Misuse of ketamine. J Am Vet Med Assoc. 1992;200:256-7.
35. United States Department of Justice. [citado 6 Oct 2006] Disponible en: www. justice.gov/ndic/pubs
36. Sociedad Española de Medicina de Familia y Comunitaria. Disponible en: http://www.semfyc.es [citado 9 Oct 2006].
37. Maxwell JC. Party drugs: properties, prevalence, patterns, and problems. Subst Use Misuse. 2005;40:1203-40.
38. Parks KA, Kennedy CL. Club drugs: reasons for and consequences of use. J Psychoactive Drugs. 2004;36:295-302.
39. Tait RJ, Hulse GK, Robertson SI, Sprivulis P. Multiple hospital presentations by adolescents who use alcohol or other drugs. Addiction. 2002;97:1269-75.
40. Darke S, Ross J, Teeson M, Lynskey M. Health service utilization and benzodiazepine use among heroin users: findings from the Australian Treatment Outcome Study (ATOS). Addiction. 2003;98:1129-35.
41. Finfgeld-Connett DL. Treatment of substance misuse in older women: using a brief intervention model. J Gerontol Nurs. 2004;30:30-7.
42. GolomboK S, Moodley P, Lader M. Cognitive impairment in long-term benzodiazepine users. Psychol Med. 1988;18:365-74.
43. Stewart SA. The effects of benzodiazepines on cognition. J Clin Psychiatry. 2005;66 Suppl 2:9-13.
44. Barker MJ, Greenwood KM, Jackson M, Crowe SF. Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: a meta-analysis. Arch Clin Neuropsychol. 2004;19:437-54.
45. Armand C, Thirion X, Saillard C, Lapeyre-Mestre M, Lambert H. Neocodion misuse: evolution between 1992 and 2002. Therapie. 2004;59:547-53.
46. Sim Mg, Hulse GK, Khong E. Cough mixtures: not always for cough. Aust fam Physician. 2004;33:327-31.
47. Murray S, Brewerton T. Abuse of over-the-counter dextromethorphan by teenagers. South Med J. 1993:86:1151-3.
48. Schwartz RH. Adolescent abuse of Dextromethorphan. Clin Pediatr (Phila). 2005;44:565-8.
49. Darboe MN. Abuse of dextromethorphan-based cough syrup as a substitute for licit and illicit drugs: a theoretical framework. Adeolescence. 1996;31:239-45.
50. Darboe MN, Keenan GR Jr, Richards TK. The abuse of dextromethorphan-based cough syrup: a pilot study of the community of Waynesboro, Pennsylvania. Adolescence. 1996;31:633-44.
51. Miller SC. Coricidin HBP cough an cold addiction. J Am Acad Child Adolesc Psychiatry. 2005;44:509-10.
52. Sharma A, Dewan V, Petty F. Acute psychosis with Coricidin cold medicine. Ann Pharmacother. 2005;39:1577-8.
53. Desai S, Aldea D, Daneels E, Soliman M, Braksmajer AS, Kopes-Kerr CP. Chronic addiction to dextromethorpahn cough syrup: a case report. J Am Board Fam Med. 2006;19:320-3.
54. Marsh LD, Key JD, Spratt E. Bulimia and dextromethorphan abuse. A cse study. J Subst Abuse Treat. 1997;14:373-6.
55. Characteristics of patients with bulimia only, bulimia with affective disorder, and bulimia with substance abuse problems. Addict Behav 1986.
56. Zawertailo LA, Busto UE, Kaplan HL, Greenblatt DJ, Sellers EM. Comparative abuse liability and pharmacological effects of meprobamate, triazolam, and butabarbital. J Clin Psychopharmacol. 2003;23:269-80.
57. Carter LP, Richards BD, Mintzer MZ, Griffiths RR. Relative abuse liability of GHB in humans: a comparison of psychomotor, subjective, and cognitive effects of supratherapeutic doses of triazolam, pentobarbital, and GHB. Neuropsychopharmacology. 2006;31:2537-51.
58. Malcom R, Book SW, Moak D, DeVane L, Czepowicz V. Clinical applications of modafinil in stimulant abusers: low abuse potential. Am J Addict. 2002;11:247-9.
59. Rush CR, Kelly TH, Hays LR, Baker RW, Wooten AF. Acute behavioural and physiological effects of modafinil in drug abusers. Behav Pharmacol. 2002;13:105-15.
60. Kruszewski SP. Euphorogenic and abusive properties of modafinil. Am J Psychiatry. 2006;163:549.
61. Mariani JJ, Hart CL. Psicosis associated with modafinil and shift work. Am J Psychiatry. 2005;162:1983.
62. Skipper GR. Tramadol abuse and dependence among physicians. JAMA. 2004;292:1818-9.
63. Comité de Expertos de la OMS en Farmacodependencia. 32.o Informe. Genève: OMS; 2001. Serie de Informes técnicos, n.o 903.
64. Comité de Expertos de la OMS en Farmacodependencia. 33.o Informe. Genève: OMS; 2003. Serie de Informes técnicos, n.o 915.
65. Zacny JP. Profiling the subjective, psicomotor, and pshysiological effects of tramadol in recreational drug users. Drug Alcohol Depend. 2005;80:273-8.
66. Golberg AB, Greenberg MB, Darney PD. Misoprostol and pregnancy. N Engl J Med. 2001;344:38-47.
67. Harper C, Ellertson CH, Winikoff B. Could American women use mifepristone-misoprostol pills safety with less medical supervision? Contraception. 2002;65:133-42.
68. Sherris J, Bingham A, Burns MA, Girvin S, Westley E, Gómez PI. Misoprostol use in developing countries: results from a multicountry study. Int J Gynaecol Obstet. 2005;88:76-81.
69. Mittal S, Agarwal S, Kumar S, Batra A. Comparison or oral versus vaginal misoprostol continued use of misoprostol after mifepristone for early medical abortion. Indian J Res. 2005;122:132-6.
70. Misoprostol. Consejo general de Colegios de Farmacéuticos. Circular 283/06. Madrid, 3 de mayo de 2006.
71. Haller CA, Jacob P 3rd, Benowitz NL. Enhanced stimulant and metabolic effects of combined ephedrine and caffeine. Clin Pharmacol Ther. 2004;75:259-73.
72. Magkos F. Kavouras SA. Caffeine and ephedrine: physiological, metabolic and performance-enhancing effects. Sports Med. 2004;34:871-9.
73. Avois L, Robinson N, Saudan C, Baume N, Mangin P, Saugy M. Central nervous system stimulants and sport practice. Br J Sports Med. 2006;40 Suppl 1:16-20.
74. Kowalczyc M, Antkowiak B, Antkowiak O, Brytan M, Zdanowski R, Klos A, et al. Ephedrine-caffeine mixture in wet-cold stress. Pharmacol Rep. 2006;58:364-2.
75. Chester N, Mottram DR, Reilly T, Powell M. Elimination of ephedrines in urine following multiple dosing: the consequences for athletes, in relation to doping control. Br J Clin Pharmacol. 2004;57:62-7.
76. OMA butlletí núm 1. Barcelona: Col•legi Oficial de Farmacèutics de Barcelona; 2006.
77. Zacny JP, Goldman RE. Characterizing the subjective, psychomotor, and physiological effects of oral prpoxyphene in non-drug-abusing volunteers. Drug Alcohol Depend. 2004;73:133-40.
78. O'Neill WM, Hanks GW, Simpson P, Fallon MT, Jenkins E, Wesnes K. The cognitive and psychomotor effects of morphine in healthy subjects: a randomized controlled trial of repetead (four) oral doses of dextropropoxiphene, morphine, lorazepam and placebo. Pain. 2000;85:209-15.
79. Isaacson JH. Preventing prescription drug abuse. Cleve Clin J Med. 2000;67:473-5.